A Quality by Design (QBD) Approach for the Development and Validation of RP-HPLC Method for the Quantification of Silymarin Tablet
Sanit J. Revankar1, Shweta M. Pandare2, M. S. Palled3, Shailendra S. Suryawanshi4
1Sanit J. Revankar, Department of Pharmaceutical Chemistry, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research, Belagavi-560010, Karnataka, India.
2Shweta M. Pandare, Department of Pharmaceutical Chemistry, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research, Belagavi-560010, Karnataka, India.
3Dr. M. S. Palled, Department of Pharmaceutical Chemistry, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research, Belagavi-560010, Karnataka, India.
4Dr. Shailendra S. Suryawanshi, Department of Pharmaceutical Chemistry, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research, Belagavi-560010, Karnataka, India.
Manuscript received on 04 July 2024 | Revised Manuscript received on 17 July 2024 | Manuscript Accepted on 15 August 2024 | Manuscript published on 30 August 2024 | PP: 9-15 | Volume-4 Issue-5, August 2024 | Retrieval Number: 100.1/ijapsr.E404604050824 | DOI: 10.54105/ijapsr.E4046.04050824
Open Access | Editorial and Publishing Policies | Cite | Zenodo | OJS | Indexing and Abstracting
© The Authors. Published by Lattice Science Publication (LSP). This is an open-access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Abstract: This study emphasizes the crucial role of Quality by Design (QbD) in developing pharmaceutical procedures, particularly in risk assessment. It demonstrates how QbD principles were applied to create a precise and effective HPLC method for Silymarin Tablets, ensuring consistent quality within specified criteria. The optimized method, developed using a Design of Experiment approach, employs a C18 column (150 mm x 4.6 mm, 5μm) with isocratic elution using a 95:25 ratio of acetonitrile to orthophosphoric acid buffer (pH 3). Peaks were detected using a PDA detector calibrated at 287 nm, with a flow rate of 1.0 mL/min. The column oven temperature was maintained at 25°C, and a 10 μL injection volume was used. Thorough validation, adhering to USP <1225> and ICH Q2 (R1) standards, ensures the method’s reliability. Key factors such as accuracy, precision, robustness, limit of detection (LOD), and limit of quantification (LOQ) were comprehensively assessed. The method exhibits exceptional sensitivity, selectivity, efficiency, precision, accuracy, and cost-effectiveness, making it ideal for pharmaceutical analysis of Silymarin tablets. It has been validated to effectively differentiate between marketed products, including those closely resembling the original. This method is intended for routine quality control analysis in the pharmaceutical industry, highlighting its suitability and reliability for ongoing use.
Keywords: AQbD, Quality by design, RP-HPLC, Silymarin, DoE, Quantification, Pharmaceutical formulations, Method development, Method validation, ICH, USP Method validation.
Scope of the Article: Pharmaceutical Analysis